With King in its fold, Pfizer — which makes Lyrica and Celebrex — believes it can build an industry-leading portfolio of pain relievers. Among King’s most appealing entrants in that market is the new Embeda, designed to prevent misuse and abuse.
Continue reading Pfizer Buys King Pharma for $3.6 Billion
Pfizer Buys King Pharma for $3.6 Billion originally appeared on DailyFinance on Tue, 12 Oct 2010 09:55:00.
Filed Under: Company News, Investing, Health Care, Pfizer, Stocks in the News